Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.

Garrett N, Reddy T, Yende-Zuma N, Takalani A, Woeber K, Bodenstein A, Jonas P, Engelbrecht I, Jassat W, Moultrie H, Bradshaw D, Seocharan I, Odhiambo J, Khuto K, Richardson SI, Omondi MA, Nesamari R, Keeton RS, Riou C, Moyo-Gwete T, Innes C, Zwane Z, Mngadi K, Brumskine W, Naicker N, Potloane D, Badal-Faesen S, Innes S, Barnabas S, Lombaard J, Gill K, Nchabeleng M, Snyman E, Petrick F, Spooner E, Naidoo L, Kalonji D, Naicker V, Singh N, Maboa R, Mda P, Malan D, Nana A, Malahleha M, Kotze P, Allagappen JJ, Diacon AH, Kruger GM, Patel F, Moore PL, Burgers WA, Anteyi K, Leav B, Bekker LG, Gray GE, Goga A. Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study. PLOS Glob Public Health 2024; 4: e0003260. CRD HIV